News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly (LLY) delivered impressive late-stage trial results for its newest weight-loss drug. UBS Global head of biotech research Michael Yee explains what this means for Novo Nordisk (NVO) and the future of the industry.
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the
Novo Nordisk (NYSE:NVO) has entered a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, and supply chain operations. The company is preparing a global rollout of the oral Wegovy weight loss pill after its US launch. Recent trial data for semaglutide and pipeline drugs such as Amycretin and CagriSema indicate further progress in obesity and metabolic disease treatments. Novo Nordisk is drawing fresh attention as it pairs an AI push with a growing...
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State
Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the...
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Eli Lilly (LLY) said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill F
(Updates with Novo Nordisk's response in the fourth paragraph.) Novo Nordisk's (NVO) Ozempic and
The findings could broaden the long-term opportunity for obesity and diabetes treatments.
While retatrutide may have the best weight loss efficacy to date, analysts hold concerns about its tolerability profile compared with best-seller, tirzepatide.
While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.
Eli Lilly said on Thursday its retatrutide cleared a late-stage trial, helping patients lose an average 29% of their weight across 80 weeks.
Eli Lilly (NYSE:LLY) has agreed to acquire Engage Biologics in a deal worth up to $202 million. Engage Biologics is developing Tethosome, a non-viral DNA delivery platform for genetic medicines. This transaction is Lilly’s seventh acquisition of 2026 and is intended to expand its genetic medicines capabilities. Eli Lilly comes into this deal with strong recent stock performance, with the share price at $1,041.65 and up 15.4% over the past 30 days and 3.5% over the past week. Over the past...
A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.
Late-stage trial data strengthens Lilly's obesity drug pipeline.
Retatrutide helped patients lose up to 28.3% of body weight over 80 weeks.
Eli Lilly and Company (NYSE:LLY), featuring a net income margin of 34.99% and upside potential of 20.64%, secures a spot on our list of the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $20.64 billion for the recently completed fiscal year (FY25). That earnings strength was […]
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
Eli Lilly’s investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.
Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome
Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.
Eli Lilly (LLY) said Thursday its investigational triple hormone receptor agonist retatrutide delive
Wall Street has rediscovered the stock-split playbook. KLA (NASDAQ: KLAC) announced a 10-for-1 forward stock split in May 2026 alongside a fiscal Q3 earnings beat and a roughly 21% dividend hike, with the stock trading in the $1,800 range. Earlier in the year, Booking Holdings (NASDAQ: BKNG) completed a 25-for-1 split announced in February 2026, taking ... Will ASML, Lilly, or TransDigm Be the Next Big Stock Split?
Eli Lilly (NYSE:LLY) shares gained around 2% in premarket trading on Thursday after the company released positive late-stage clinical trial results for its experimental obesity treatment retatrutide. The study showed that patients diagnosed with obesity lost an average of 28.
Demand for weight loss drugs may fuel growth for more than one player.